Cognito Therapeutics
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
55 Cambridge Pkwy Ste 102W, Cambridge, M...Phone Number
(857) 201-5088Website
www.cognitotx.comRevenue
$10.6 MillionIndustry
ZI Rank: 2
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
2
3
1
1
1
2
About Cognito Therapeutics
Cognito Therapeutics is a pioneer in disease-modifying therapeutic interventions for neurodegenerative diseases and human cognitive performance. The company has completed multiple clinical studies demonstrating its investigational therapeutic platform has the potential to safely slow or stop cognitive decline and loss of brain volume in Alzheimer's disease. Cognito has received FDA Breakthrough Device Designation treatment of the cognitive and functional symptoms associated with Alzheimer's disease in individuals diagnosed with mild to moderate Alzheimer's and expects to start pivotal studies in 2022. The company's technology was based on pioneering optogenetics research by scientific co-founders Professors Li-Huei Tsai and optogenetics pioneer Ed Boyden at MIT.Explore more
Cognito Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cognito Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Cognito Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Cognito Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Cognito Therapeutics
Website visits: Recent activity has been detected on your website
Check out if Cognito Therapeutics is spiking on competitors!
Click to see if Cognito Therapeutics had a recent Job posting/layoffs
Cognito Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Cognito Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Cognito Therapeutics launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Cognito Therapeutics
Compare insights from companies similar to Cognito Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
<$5M
11-50
Private
<$5M
2005
CL
Cynthia LevinthalPrincipal Consultant. Neural Stem Cell Therapies. Clinical Trials
Company Profile Activity
Activity Insights
Cognito Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Cognito Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Cognito Therapeutics.
Cognito Therapeutics financials insights
Gather financial insights about Cognito Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Unspecified
$50M
2023
Series B
$108M
2024
Series B
$35M
2026
Series C
$105M
Cognito Therapeutics Tech Stack
A closer look at the technologies used by Cognito Therapeutics
Most Recent Scoops
Open Position
Open Position
Person-Based
Medical Research, Regulations
Open Position
Person-Based
Executive Moves, Clinical Operations
Cognito Therapeutics News & Media
Cognito Therapeutics and Ochsner partner for new brain health approaches
The Collaboratory leverages the expertise of Ochsner Health’s Neuroscience Institute.Cognito Therapeutics Nets $105 Million Series C
CAMBRIDGE, MA, Cognito Therapeutics, a late clinical-stage neurotechnology company, announced the final close of its oversubscribed $105 million Series C funding.$105 Million Brings Cognito, And Neurotech, to a Pivotal Stage - Forbes
Cognito's $105 million Series C will advance their pivotal FDA study, expand clinical neurology partnerships, and expand work past Alzheimer's into Parkinsons and beyond.Cognito Therapeutics Raises $105M Series C Led by Morningside Ventures to Advance ...
Cognito Therapeutics, a Massachusetts-based neurotechnology company developing non-invasive therapies for neurodegenerative disorders, has closed an oversubs...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Cognito Therapeutics
Sign Up For FreeTo access detailed company insights
Cognito Therapeutics is a pioneer in disease-modifying therapeutic interventions for neurodegenerative diseases and human cognitive performance. The company has completed multiple clinical studies demonstrating its investigational therapeutic platform has the potential to safely slow or stop cognitive decline and loss of brain volume in Alzheimer's... Read More
